Get the Stockscreener App
13.95
5.20%
0.69
After Hours:
13.96
0.01
+0.07%
Jade Biosciences Inc stock is traded at $13.95, with a volume of 375.03K.
It is up +5.20% in the last 24 hours and down -3.79% over the past month.
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
See More
Previous Close:
$13.26
Open:
$13.58
24h Volume:
375.03K
Relative Volume:
1.06
Market Cap:
$687.96M
Revenue:
-
Net Income/Loss:
$-91.76M
P/E Ratio:
-2.5577
EPS:
-5.4541
Net Cash Flow:
$-94.89M
1W Performance:
+1.23%
1M Performance:
-3.79%
6M Performance:
+73.08%
1Y Performance:
+0.00%
1-Day Range:
$13.53
$14.17
1-Week Range:
$12.91
$14.34
52-Week Range:
$6.565
$17.71
Jade Biosciences Inc Stock (JBIO) Company Profile
Name
Jade Biosciences Inc
Sector
Industry
Phone
(781) 312-3013
Address
221 CRESCENT ST., WALTHAM
Compare JBIO vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
13.95 | 653.93M | 0 | -91.76M | -94.89M | -5.4541 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Initiated | BTIG Research | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jun-16-25 | Upgrade | Guggenheim | Neutral → Buy |
| May-07-25 | Initiated | Wedbush | Outperform |
| May-05-25 | Initiated | Stifel | Buy |
| May-02-25 | Initiated | TD Cowen | Buy |
| Jun-18-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-18-24 | Downgrade | TD Cowen | Buy → Hold |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-17-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-17-24 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-25-24 | Resumed | Jefferies | Buy |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Dec-06-22 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-16-22 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Jul-26-21 | Initiated | Cowen | Outperform |
| Jul-26-21 | Initiated | Evercore ISI | Outperform |
| Jul-26-21 | Initiated | Jefferies | Buy |
| Jul-26-21 | Initiated | Wedbush | Outperform |
View All
Jade Biosciences Inc Stock (JBIO) Latest News
JBIO Analyst Rating Update: HC Wainwright Raises Price Target to $35 | JBIO Stock News - GuruFocus
H.C. Wainwright raises Jade Biosciences stock price target to $35 By Investing.com - Investing.com Canada
Jade Biosciences (NASDAQ:JBIO) Price Target Raised to $35.00 at HC Wainwright - MarketBeat
Jade Biosciences, Inc.(NasdaqCM: JBIO) added to S&P Biotechnology Select Industry Index - marketscreener.com
Wall Street Analysts Predict a 52.5% Upside in Jade Biosciences, Inc. (JBIO): Here's What You Should Know - MSN
BTIG raises Jade Biosciences stock price target on pricing outlook By Investing.com - Investing.com Canada
Portfolio Recap: Is Jade Biosciences Inc forming a bullish divergenceWeekly Trading Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Jade Biosciences (NASDAQ:JBIO) Shares Gap Up After Analyst Upgrade - MarketBeat
Jade Biosciences (NASDAQ:JBIO) Price Target Raised to $39.00 at BTIG Research - MarketBeat
Jade Biosciences (NASDAQ:JBIO) Cut to Strong Sell at Zacks Research - Defense World
Jade Biosciences (NASDAQ:JBIO) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
Zacks Research Downgrades Jade Biosciences (NASDAQ:JBIO) to Strong Sell - MarketBeat
Guggenheim Forecasts Strong Price Appreciation for Jade Biosciences (NASDAQ:JBIO) Stock - MarketBeat
Guggenheim raises Jade Biosciences stock price target on pipeline progress By Investing.com - Investing.com Canada
William Blair Upgrades Jade Biosciences (NASDAQ:JBIO) to Strong-Buy - Defense World
Jade Biosciences (NASDAQ:JBIO) Sees Large Volume Increase Following Analyst Upgrade - Defense World
Jade Biosciences (NASDAQ:JBIO) Sees Unusually-High Trading Volume Following Analyst Upgrade - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Jade Biosciences (NASDAQ:JBIO) Raised to "Strong-Buy" at William Blair - MarketBeat
TD Cowen reiterates Jade Biosciences stock rating on APRIL data By Investing.com - Investing.com Canada
William Blair initiates Jade Biosciences stock coverage with Outperform rating - Investing.com UK
Trading Recap: Is Jade Biosciences Inc a speculative investment2026 Breakouts & Accurate Buy Signal Alerts - baoquankhu1.vn
Wedbush Reaffirms Outperform Rating for Jade Biosciences (NASDAQ:JBIO) - MarketBeat
William Blair initiates Jade Biosciences stock coverage with Outperform rating By Investing.com - Investing.com India
Signal Recap: Is Jade Biosciences Inc a speculative investment2026 Historical Comparison & Weekly Stock Performance Updates - baoquankhu1.vn
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Jade Biosciences (NASDAQ:JBIO) Raised to “Strong-Buy” at Lifesci Capital - Defense World
Jade Biosciences (NASDAQ:JBIO) Upgraded by Lifesci Capital to "Strong-Buy" Rating - MarketBeat
Jade 10-K: $127.4M net loss, cash and investments $336.2M - TradingView
BTIG reiterates Buy on Jade Biosciences stock, $28 target maintained By Investing.com - Investing.com Canada
Stifel raises Jade Biosciences price target on IgAN market outlook By Investing.com - Investing.com South Africa
Stifel raises Jade Biosciences price target on IgAN market outlook - Investing.com
Jade Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Jade Biosciences reports fourth quarter and full year 2025 financial results and provides corporate update - marketscreener.com
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times
Jade Biosciences reports Q4 EPS ($3.19), consensus ($2.95) - TipRanks
Jade Biosciences Stock Quote, Share Price, News and Analysis - Longbridge
Jade Biosciences Touts “Best-in-Class” Autoimmune Antibodies, JADE101 Phase 1 Readout Nears - Defense World
JBIO Should I Buy - Intellectia AI
JBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO), Context Therapeutics (CNTX) and MBX Biosciences, Inc. (MBX) - The Globe and Mail
Oppenheimer 36th Healthcare Life Sciences Conference: Spotlight On LGND, PHAR, CRBP, Among Others - RTTNews
Chipmakers Recap: Is Jade Biosciences Inc a stock for growth or value investors2025 Top Gainers & Long-Term Investment Growth Plans - baoquankhu1.vn
Can Jade Biosciences Inc. expand its profit marginsWeekly Profit Recap & Safe Entry Zone Tips - Mfd.ru
Jade Biosciences (JBIO) grants RSUs and 247,500-share option to officer - Stock Titan
Weekly Earnings: Is Jade Biosciences Inc a speculative investmentJuly 2025 Spike Watch & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Jade Biosciences to Participate in Upcoming Conferences - Yahoo Finance
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Jade Biosciences (NASDAQ:JBIO) Shares Gap UpHere's Why - MarketBeat
Jade Biosciences, Inc. (NASDAQ:JBIO) Short Interest Update - MarketBeat
Aug Sentiment: Is Jade Biosciences Inc a speculative investment2025 Top Gainers & Long-Term Investment Growth Plans - baoquankhu1.vn
Jade Biosciences Inc Stock (JBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):